Recognition determinants of broadly neutralizing human antibodies against dengue viruses

@article{Rouvinski2015RecognitionDO,
  title={Recognition determinants of broadly neutralizing human antibodies against dengue viruses},
  author={Alexander Rouvinski and Pablo Guardado-Calvo and Giovanna Barba-Spaeth and St{\'e}phane Duquerroy and Marie Christine Vaney and Carlos Kikuti and M. E. Navarro Sanchez and Wanwisa Dejnirattisai and Wiyada Wongwiwat and Ahmed Haouz and Christine Girard-Blanc and St{\'e}phane Petres and William E Shepard and Philippe Despr{\`e}s and Fernando Arenzana‐Seisdedos and Philippe Dussart and Juthathip Mongkolsapaya and Gavin R. Screaton and F{\'e}lix A. Rey},
  journal={Nature},
  year={2015},
  volume={520},
  pages={109-113}
}
Dengue disease is caused by four different flavivirus serotypes, which infect 390 million people yearly with 25% symptomatic cases and for which no licensed vaccine is available. Recent phase III vaccine trials showed partial protection, and in particular no protection for dengue virus serotype 2 (refs 3, 4). Structural studies so far have characterized only epitopes recognized by serotype-specific human antibodies. We recently isolated human antibodies potently neutralizing all four dengue… 
A dengue monovalent vaccine with novel structure provides cross-protection against four serotypes of dengue virus
TLDR
It is shown that mice vaccinated with highly matured virus-like particles derived from DENV serotype 2 (mD2VLP) can generate higher and broader neutralization antibodies (NtAbs) against all 4 serotypes of DENV through clonal expansion supported by hybridoma and B-cell repertoire analysis.
A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus
TLDR
The findings showed the candidate (SIgN-3C-LALA) reduced blood-virus levels, protected from lethal infection, and also offered improved safety—without compromising efficacy—the latter by way of intentional mutations to the antibody’s structure.
Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1
TLDR
The studies demonstrate that it is possible to transplant a large number of discontinuous residues between DENV serotypes and partially recreate a complex antibody epitope, while retaining virus viability, and demonstrates the technical feasibility of engineering dengue viruses to display targets of protective antibodies.
Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera
TLDR
It is reported that neutralization of DENV serotype 1 by polyclonal antibody is impacted by minor sequence variation among virus strains, suggesting that mechanisms that control neutralization sensitivity extend beyond variation within antibody epitopes but also include the influence of single amino acids on the ensemble of structural states sampled by structurally dynamic virions.
Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine
TLDR
Investigation of the binding of 22 human monoclonal antibodies to the DENV envelope protein on particles with different maturation states suggests that mature particles may be the optimal form of presentation of the envelope protein to induce more potent neutralizing antibodies against DENV.
Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development
TLDR
Progress is outlined in understanding of mouse mAbs, human m Abs, and polyclonal sera against DENV envelope and precursor membrane proteins, two surface proteins involved in vaccine development, following natural infection; analyses have provided valuable insight into new strategies involving molecular technology to induce more potent neutralizing antibodies and less enhancing antibodies for next-generation dengue vaccine development.
An epitope-resurfaced virus-like particle can induce broad neutralizing antibody against four serotypes of dengue virus
TLDR
It is shown for the first time that mD2VLP particles possess a T=1 icosahedral symmetry with a groove located within the E-protein dimers near the 2-fold vertices that exposed highly overlapping, cryptic neutralizing epitopes through cryo-electron microscopy reconstruction.
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
TLDR
The results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.
...
...

References

SHOWING 1-10 OF 50 REFERENCES
The Structural Basis for Serotype-Specific Neutralization of Dengue Virus by a Human Antibody
TLDR
Describing the isolation of a neutralizing antibody from a DENV1-infected patient and demonstrating that the antibody binds across two adjacent viral envelope proteins and identifying the amino acids that comprise the binding site provide a structural and molecular context for durable, serotype-specific immunity to DENV infection.
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions
TLDR
It is demonstrated that the dengue virus (DENV)-specific serum Ab response in humans consists of a large fraction of cross-reactive, poorly neutralizing Abs and a small fraction of serotype-specific, potently inhibitory Abs.
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
TLDR
The results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.
Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus
TLDR
It is shown that human sera from patients recovering from DENV‐4 infection contain antibodies that bind to the 5H2 epitope region on domain I, which provides new information and tools for effective vaccine design to prevent dengue disease.
Variation of the Specificity of the Human Antibody Responses after Tick-Borne Encephalitis Virus Infection and Vaccination
TLDR
New in vitro assays for dissecting the antibody populations present in blood serum and determining their contribution to virus neutralization are developed, indicating substantial influences of individual-specific factors that control the specificity of the antibody response.
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins
The monoclonal antibody 1A1D-2 has been shown to strongly neutralize dengue virus serotypes 1, 2 and 3, primarily by inhibiting attachment to host cells. A crystal structure of its antigen binding
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354
TLDR
The cross-linking of the six E monomers within one raft by four CR4354 Fab fragments suggests that the antibody neutralizes WNV by blocking the pH-induced rearrangement of the E protein required for virus fusion with the endosomal membrane.
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
TLDR
A viral antigen is sought that provides greater protection than currently available vaccines and focused on antigenic site Ø, a metastable site specific to the prefusion state of the RSV fusion (F) glycoprotein, as this site is targeted by extremely potent RSV-neutralizing antibodies.
A Fusion-Loop Antibody Enhances the Infectious Properties of Immature Flavivirus Particles
TLDR
It is observed that E53-opsonized immature DENV particles but not WNV particles required a more acidic pH for efficient cleavage of prM by furin, adding greater complexity to the dynamics of antibody-mediated infection of immature flavivirus virions.
...
...